Final overall survival data from the Phase 3 ROSELLA trial show that relacorilant (Lifyorli) added to nab-paclitaxel significantly improves outcomes in platinum-resistant ovarian cancer. At the 2026 SGO Annual Meeting, the regimen reduced the risk of death by 35% versus nab-paclitaxel alone (HR 0.65; P = .0004), extending median OS from 11.9 to 16.0 months. The report also noted consistent benefits across prespecified subgroups, including patients with and without prior PARP inhibitor exposure and across platinum-free interval strata. The combination received FDA approval in March 2026 and is now listed as a preferred option in NCCN guidelines for platinum-resistant disease.